A patent application published on July 16, 2026 and assigned to Edwards Lifesciences Corporation is directed to something the transcatheter valve business does not usually try to claim: the act of measuring a patient before choosing a device. US20260199086A1, titled PROSTHETIC HEART VALVES AND METHODS FOR SUPRA-ANNULAR IMPLANTATION, names Nikolai Gurovich and Tamir S. Levi as inventors and is classified under A61F 2/2418, A61F 2/2436 and A61F 2220/0008. It is a pending application — published, not granted — and what it claims is a set of methods rather than a valve.

That distinction is the commercial tell. Claim 1 recites four steps a physician performs: inserting a delivery apparatus carrying the valve in a radially compressed state into the patient's vasculature; advancing it until the compressed valve is within the aortic root; aligning it against anatomical features of the root; and radially expanding it. The limitation that separates claim 1 from routine transcatheter aortic valve replacement arrives in the closing wherein clause, which requires that once expanded, the inflow end of the frame is above the annulus of the aortic valve and the outflow end of the frame is below the sinotubular junction, or STJ. Conventional transcatheter aortic valves are typically seated partly within or below the annulus. Claim 1 stakes out the narrower landing zone entirely between the two landmarks — the supra-annular positioning of the title.

Landing a frame in that window is a geometry problem before it is a technique problem, and the dependent claims say so. Claim 8 adds the precondition that a height of the frame is less than the distance between the annulus and the STJ. Claim 9 puts a number on it, reciting a frame height in a range of 15.5 mm to 22.5 mm. Those are the two facts that turn the concept into a product specification: a valve that intends to sit between the landmarks has to be short enough to fit between them, and the application discloses the band Edwards is working in.

The claim that starts with a measurement

Claim 14 is where the filing reads most clearly as a commercial signal rather than a bench idea. It is a second independent method — a method of treating an aortic valve of a patient — and it front-loads the sizing logic that claim 8 handles as a dependent limitation. Instead of assuming a suitably short valve, claim 14 makes the measurement and the selection the first two steps of the claimed method:

determining a distance between an annulus and an STJ of an aortic root of the patient; selecting a prosthetic heart valve that has a height in a radially expanded state that is less than the distance between the annulus and the STJ— PROSTHETIC HEART VALVES AND METHODS FOR SUPRA-ANNULAR IMPLANTATION, US20260199086A1

Read as a business document, that ordering matters. A method claim that opens with imaging-derived measurement and device selection is directed to the workflow around the implant, not only the implant. Claim 16 carries the same 15.5 mm to 22.5 mm height band into that second independent claim, which means the sizing range travels with the selection step. Claim 17 then supplies a third, stripped-down independent method covering only the expansion step and the resulting position — the same above-the-annulus, below-the-STJ placement recited in claim 1, with the catheter navigation stripped out. Three independent claims approaching one placement concept from three altitudes is a structural choice, and it suggests the applicant is trying to capture the idea whether it shows up as a technique, as a sizing protocol, or as the deployed end state.

The rest of the dependent set fills in the failure mode this positioning invites. If the frame no longer overlaps the annulus, it loses the anchoring that annular seating conventionally provides, and claims 10 through 13 respond with anti-migration hardware: deploying one or more frame anchors over a native leaflet free edge, engaging an annular flange of an outer skirt with native tissue above the annulus, and an ingrowth-resistant annular extension that extends into the annulus. Claims 4 through 7 describe the expanded valve's interaction with the native leaflets and with the top wall of the aortic root below the STJ. The application's abstract, as background description, frames the whole disclosure around preventing or limiting migration of an implanted prosthetic valve — which is consistent with a design where retention has to be re-solved once the frame moves off the annulus.

Where the cohort points

This application does not stand alone. Edwards Lifesciences publications in the same recent window cluster around the components that a supra-annular seating strategy would need. US20260137510A1, on prosthetic valves and delivery assemblies with positioning arms, is the closest sibling on axial positioning. US20260191639A1 claims a sealing member for a prosthetic heart valve, and US20260137514A1 covers a prosthetic heart valve having a skirt with a thromboresistant portion — both in the same territory as the outer-skirt flange recited here. US20260183104A1 and US20260183105A1 address the valve and its leaflet attachment, while US20260151596A1, a hybrid expandable sheath, sits on the delivery side. Read together, the group describes a full stack rather than a single point solution, and it puts positioning, sealing and skirt engineering in the same publication window.

Two things in the published text remain unresolved, and both are worth flagging plainly rather than smoothing over. First, the directional vocabulary is not consistent across the independent set. Claims 1, 14 and 17 and the abstract use anatomical terms — the inflow end above the annulus, the outflow end below the STJ. Claims 18 and 20 instead use flow-direction terms, reciting an entirety of the frame, and then of the valve, within the aortic root "upstream of the annulus of the aortic valve and downstream of the STJ" after expansion. Because aortic blood travels from the annulus toward the STJ, those two vocabularies read literally as opposite placements. The application as published contains both, and reconciling them is prosecution's job, not a reader's.

Second, the published claim set carries drafting artifacts. Claim 15 is missing its transitional phrase and is grammatically incomplete as published, and claim 19 recites "either of" against a single antecedent claim. Separately, claims 2 and 3 position the inflow end below the annulus and the outflow end above the STJ — the reverse of claim 1's wherein clause — but they describe the alignment stage while the valve is still radially compressed, during alignment, not the deployed expanded state that claim 1 requires. That staging distinction is what keeps them consistent with claim 1.

None of that changes what the filing signals commercially. Edwards is claiming a placement window defined by two anatomical landmarks, a device height band that fits inside it, anti-migration features to hold it there, and — in claim 14 — the measurement-then-selection workflow that decides whether a given patient is a candidate at all. Whether any of it issues, and in what form, is now a matter of prosecution.